Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
How Are ARIs Being Used to Intensify Therapy for High-Risk Localized Prostate Cancer After Local Therapy?
How Are ARIs Being Used to Intensify Therapy for High-Risk Localized Prostate Cancer After Local Therapy?
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
The Great Debate Surrounding Dietary Sodium: The Peril of Applying Population Statistics to Individual Patients
The Great Debate Surrounding Dietary Sodium: The Peril of Applying Population Statistics to Individual Patients